retatrutide phase 2 trial obesity triple agonist Retatrutide, a (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished When the Breakthrough Obesity G-Agonist

While this explanation is an oversimplification of the process, a comprehensive review is found elsewhere [56]

As with many wellness supplements, individual results seem to vary based on factors such as diet, activity level, metabolism, and consistency of use

GLP-1 provides the appetite suppression foundation, but GIP fundamentally changes how the body responds metabolically in ways that dramatically amplify weight loss beyond what GLP-1 alone achieves

They werent just sipping the Kool-Aid (or should I say, soda?)

Some subjects lost 20%

2026/04/02 10 WEB24 GLP-1 20264NEJM 20264 GLP-1 BMJ Medicine 2026 SURMOUNT-4 eClinicalMedicine 2026 New England Journal of MedicineNEJM202642 GLP-1 GLP-1 Rosen CJ, Ingelfinger JR